2 weeks Ago By Defense World Staff
Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report ) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company.
The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $77.77. A number of equities research analysts recently issued reports on EXAS shares.
Wells Fargo & Company started coverage on Exact Sciences in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price objective on the stock.
The Goldman Sachs Group decreased their price objective on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th.
Scotiabank initiated coverage on shares of Exact Sciences in a research report on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 target price for the company.
Benchmark decreased their price target on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, August 1st.
Finally, BTIG Research reduced their price objective on Exact Sciences from $80.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, June 26th.
Get Our Latest Stock Analysis on Exact Sciences Exact Sciences Trading Down 2.9 % Exact Sciences ( NASDAQ:EXAS – Get Free Report ) last posted its earnings results on Wednesday, July 31st. The medical research company reported ($0.
09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28.
Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%.
The business had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million.
During the same quarter in the previous year, the firm earned ($0.45) EPS. The company’s quarterly revenue was up 12.
4% compared to the same quarter last year. As a group, analysts expect that Exact Sciences will post -0.87 EPS for the current year.
Insiders Place Their Bets In other news, EVP Brian Baranick sold 929 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total value of $65,030.
00. Following the completion of the transaction, the executive vice president now owns 13,687 shares of the company’s stock, valued at approximately $958,090. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink .
Company insiders own 1.36% of the company’s stock. Institutional Investors Weigh In On Exact Sciences Several hedge funds have recently added to or reduced their stakes in the stock.
Asahi Life Asset Management CO. LTD. grew its position in Exact Sciences by 4.
2% in the 4th quarter. Asahi Life Asset Management CO. LTD.
now owns 4,390 shares of the medical research company’s stock worth $325,000 after purchasing an additional 175 shares during the period. Perigon Wealth Management LLC raised its stake in shares of Exact Sciences by 2.1% in the first quarter.
Perigon Wealth Management LLC now owns 8,516 shares of the medical research company’s stock worth $588,000 after buying an additional 175 shares during the period. Benjamin F. Edwards & Company Inc.
increased its holdings in Exact Sciences by 65.6% in the 1st quarter. Benjamin F.
Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after acquiring an additional 179 shares in the last quarter. Sanders Morris Harris LLC raised its stake in Exact Sciences by 4.
2% during the 1st quarter. Sanders Morris Harris LLC now owns 5,000 shares of the medical research company’s stock worth $345,000 after acquiring an additional 200 shares during the period. Finally, Daiwa Securities Group Inc.
lifted its holdings in Exact Sciences by 1.7% during the first quarter. Daiwa Securities Group Inc.
now owns 11,947 shares of the medical research company’s stock valued at $825,000 after purchasing an additional 200 shares in the last quarter. 88.82% of the stock is owned by institutional investors.
About Exact Sciences ( Get Free Report Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Stories Five stocks we like better than Exact Sciences How to Use the MarketBeat Dividend Calculator Simon Property REIT: A Safe Bet for Growth and Steady Dividends Best Stocks Under $10.00 CarMax’s Impressive Rally: What Investors Should Watch Next Using the MarketBeat Dividend Tax Calculator MarketBeat Week in Review – 9/23 – 9/27 Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
